Antihyperlipidemic agent, specifically a statin (HMG-CoA reductase inhibitor).

Hyperlipidemia: For the management of elevated cholesterol (LDL, total cholesterol) and triglyceride levels.
Primary prevention of cardiovascular disease: To reduce the risk of heart attacks, strokes, and related complications in individuals with high cholesterol and those at high risk for heart disease.
Secondary prevention: To reduce the risk of further cardiovascular events (e.g., heart attack, stroke) in patients who have already experienced one.
Hyperlipoproteinemia: To treat disorders associated with elevated lipid levels in the blood.
Familial hypercholesterolemia: In patients with genetically high cholesterol.

Rosuvastatin works by inhibiting the enzyme HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This inhibition reduces the production of cholesterol in the liver, leading to a decrease in blood cholesterol levels, particularly LDL cholesterol. This reduces the risk of atherosclerosis (plaque buildup in arteries), and subsequent cardiovascular events like heart attack and stroke. Additionally, rosuvastatin may enhance the liver’s ability to remove LDL cholesterol from the blood by increasing the number of LDL receptors on liver cells